Jeffrey W. Dunn Sells 1,609 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) Director Jeffrey W. Dunn sold 1,609 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $12.43, for a total transaction of $19,999.87. Following the completion of the sale, the director now directly owns 20,431 shares in the company, valued at approximately $253,957.33. This represents a 7.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

SI-BONE Stock Performance

SI-BONE stock traded down $0.17 during mid-day trading on Wednesday, hitting $12.15. 217,144 shares of the company’s stock traded hands, compared to its average volume of 392,037. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The firm has a 50 day simple moving average of $13.91 and a two-hundred day simple moving average of $14.26. SI-BONE, Inc. has a fifty-two week low of $11.76 and a fifty-two week high of $21.70. The stock has a market cap of $509.57 million, a price-to-earnings ratio of -13.39 and a beta of 1.22.

Wall Street Analysts Forecast Growth

SIBN has been the subject of a number of recent research reports. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of SI-BONE in a research note on Wednesday. Truist Financial upped their price objective on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Morgan Stanley lowered their target price on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $23.00.

Institutional Trading of SI-BONE

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bellevue Group AG lifted its position in SI-BONE by 810.5% during the first quarter. Bellevue Group AG now owns 1,139,956 shares of the company’s stock worth $18,661,000 after acquiring an additional 1,014,756 shares during the last quarter. Harbor Capital Advisors Inc. increased its holdings in shares of SI-BONE by 222.5% during the third quarter. Harbor Capital Advisors Inc. now owns 620,490 shares of the company’s stock worth $8,674,000 after buying an additional 428,110 shares in the last quarter. American Century Companies Inc. raised its stake in shares of SI-BONE by 22.8% during the second quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock valued at $25,685,000 after acquiring an additional 368,637 shares during the last quarter. Champlain Investment Partners LLC increased its stake in shares of SI-BONE by 14.7% in the third quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock valued at $39,145,000 after buying an additional 358,821 shares during the period. Finally, Paradigm Capital Management Inc. NY boosted its stake in shares of SI-BONE by 24.7% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 1,349,400 shares of the company’s stock valued at $17,448,000 after purchasing an additional 267,100 shares during the last quarter. Institutional investors own 98.11% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.